Ipamorelin

Participants:

adults with mild cognitive impairment and healthy older adults

Study Quality Assessment:

controlled trial

Findings:

Ghrelin mimetics HM01 (globally active) and ipamorelin (peripherally restricted) significantly attenuated colonic hypersensitivity and somatic allodynia in a rat model of non-inflammatory visceral hypersensitivity. These anti-nociceptive effects were blocked by a ghrelin receptor antagonist, indicating ghrelin receptor-mediated mechanisms are involved. The findings suggest a potential novel approach for treating acute visceral and somatic pain using ghrelin mimetics.

Participants:

Animal model: rats

Dosage:

HM01 administered orally (p.o.) at doses of 1, 3, 10, 30 mg/kg. Ipamorelin (IPAM) administered intravenously (i.v.) at doses of 0.01, 0.1, 1.0 mg/kg. The ghrelin receptor antagonist H0900 was administered orally.

Study Quality Assessment:

Experimental model in rats. Visceral hypersensitivity induced by dilute acetic acid (0.6%) infusion in the colon. Colonic sensitivity assessed via visceromotor behavioral response (VMR) to colorectal distension (CRD). Somatic mechanical allodynia quantified by paw withdrawals to von Frey filament. Compared to vehicle controls. Sample size n=4-6/group for HM01 and ipamorelin experiments. Conflict of interest statement provided: one author reports grants from Helsinn Pharma; two other authors report past or current employment/consultancy with Helsinn entities.

All Effects:

Findings:

Ipamorelin is effective in stimulating growth hormone release in adults with GHD and has potential benefits for improving lean body mass and muscle strength in elderly patients.

Participants:

adults with GHD, elderly patients

Study Quality Assessment:

Studied in clinical trials and case studies.

Findings:

The text states that the development and pharmacology of ipamorelin, a new potent growth hormone (GH) secretagogue, are described. Ipamorelin is identified as a pentapeptide.

Authors:

Osterziel, K. J. et al.

Findings:

Treatment with recombinant human growth hormone (rhGH) significantly increased left-ventricular mass in patients with dilated cardiomyopathy compared to placebo. However, this was not accompanied by improvements in left-ventricular systolic wall stress, mean blood pressure, systemic vascular resistance, New York Heart Association functional class, left-ventricular ejection fraction, or 6 min walking test distance. Changes in left-ventricular mass were significantly related to changes in serum insulin-like growth factor (IGF)-I concentrations.

Participants:

50 patients (43 men) with chronic heart failure due to dilated cardiomyopathy.

Dosage:

Subcutaneous rhGH (2 IU daily) or placebo for a minimum of 12 weeks.

Study Quality Assessment:

Randomised, double-blind, placebo-controlled study. N=50 patients. Data were analysed by intention to treat.

All Effects: